Emergent BioSolutions revealed this week plans to expand its viral vector and gene therapy capabilities.
The company announced it will invest $75 million in its Canton, Mass., facility, which is focused on the contract development and manufacturing (CDMO) of drug substances for live viral vaccines, including the company’s smallpox vaccine